- AIM-102 is the first of a new class of oral, non-steroidal, immune modulating anti-inflammatory drugs
- AIM-102 offers a potentially safer, more convenient treatment for moderate to severe asthma, one of the most prevalent chronic diseases in major markets
TORONTO, Oct. 22, 2012 /CNW/ - AIM Therapeutics Inc. announced today its lead drug candidate, AIM-102 has commenced dosing in a multi-site Phase II clinical trial. AIM-102 is the first of a new class of oral, non-steroidal, immune-modulating anti-inflammatory drugs targeting the large therapeutic markets of asthma and chronic obstructive pulmonary disease [COPD].
The Phase II trial is a double-blind, placebo-controlled, cross-over study to evaluate the efficacy, safety, tolerability, pharmacodynamics and pharmacokinetics of oral administration of AIM-102 in patients with mild to moderate allergic asthma. Study subjects will receive either placebo or a single dose of AIM-102 over a 3 day period in an established and clinically validated allergen challenge model with physiological and plasma measurements being taken at regular intervals. Trial enrolment has been completed, with results expected by the end of Q1, 2013. The company then plans to enter into one or more partnerships with leaders in the field of asthma drug development to undertake larger scale efficacy studies.
AIM Therapeutics Inc. is collaborating with the Clinical Investigator Collaborative (CIC) of AllerGen NCE, one of Canada's national Networks of Centres of Excellence, to evaluate the potential for AIM-102 as a novel treatment for asthma, utilizing the CIC's allergen challenge model. The CIC is well-known internationally for its leadership in the testing and assessment of new asthma medications. Dr. Paul O'Byrne, AllerGen NCE Principal Investigator and Professor and Chair, Department of Medicine, McMaster University, states that "the AllerGen Network is pleased to be associated with this study. It views AIM-102 as a unique compound, not only in terms of its derivation, but in terms of its strategic positioning as a non-steroidal therapeutic option for the management of asthma."
When announcing the start of the trial today, Frank Gleeson, President & CEO hailed it as a pivotal step towards validating AIM-102's potential as a novel treatment option for asthmatics. "AIM-102 is a novel medication which has consistently shown a favourable safety profile throughout pre-clinical and Phase I testing. We are delighted to be commencing a Phase II trial in conjunction with global leaders at the AllerGen Network to assess AIM-102's potential for efficacy in treating asthma. The start of this trial represents a major milestone for AIM Therapeutics Inc., building on close to twenty years of pioneering basic research by a team of AllerGen investigators led by Dr. Dean Befus, Professor at the University of Alberta into new mechanisms by which the natural interrelations among the nervous, immune and endocrine systems can be harnessed to treat disease."
About AIM Therapeutics Inc.
AIM Therapeutics Inc. [AIM] is a clinical stage company pioneering a new class of non-steroidal, immune modulating, anti-inflammatory drugs for chronic inflammatory conditions. AIM's proprietary compounds exploit novel discoveries related to powerful natural interactions between the nervous, immune and endocrine systems to treat disease. Effective and potentially safer - our product development pipeline promises to transform treatment regimes in the multi-billion dollar respiratory markets of asthma and chronic obstructive pulmonary disease [COPD].
About AllerGen NCE
AllerGen NCE Inc., the Allergy, Genes and Environment Network, is a national research network dedicated to improving the quality of life for people living with allergic and related immune diseases. AllerGen is funded by Industry Canada through the federal Networks of Centres of Excellence (NCE) program. The Network is hosted at McMaster University in Hamilton, Ontario. Since inception in 2004, AllerGen has been supporting excellence in research and fostering commercialization, social innovation and knowledge mobilization that will enable Canadians to better prevent, treat and manage allergy, asthma, anaphylaxis and related immune diseases. Leading Canadian experts are working in trans-disciplinary teams, with national and international collaborators, and stakeholder and research partner organizations, to address knowledge gaps and create new opportunities in diagnostics, therapeutics, healthcare, public health, ethics, policy and patient education. Network participants are also training the next generation of researchers, innovators and clinician-scientists, while collaboratively working to reduce the morbidity, mortality and socio-economic impacts of allergic diseases. For more information, visit www.allergen-nce.ca.
SOURCE: AIM Therapeutics Inc.
For further information:
AIM Therapeutics Contact:
President & CEO
T: 647 237 3691
AllerGen NCE Contact:
Dr. Paul O'Byrne
Professor and Chair, Department of Medicine, McMaster University
AllerGen Clinical Investigator Collaborative (CIC) Legacy Project Leader
T: 905-521-2100 x76373